Amicus Therapeutics, Inc. (LON:0HF9)

Market Cap	1.92B
Revenue (ttm)	416.89M
Net Income (ttm)	-27.81M
Shares Out	n/a
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	15.10
Dividend	n/a
Ex-Dividend Date	n/a

Volume	396
Average Volume	1,836
Open	8.30
Previous Close	8.43
Day's Range	8.18 - 8.30
52-Week Range	5.54 - 12.54
Beta	n/a
RSI	54.74
Earnings Date	Nov 5, 2025

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration an...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2002
• Employees: 499
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0HF9

Financial Performance

In 2024, Amicus Therapeutics's revenue was $528.30 million, an increase of 32.29% compared to the previous year's $399.36 million. Losses were -$56.11 million, -62.99% less than in 2023.

Financial numbers in USD